Compare MDGL & KD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MDGL | KD |
|---|---|---|
| Founded | 2011 | 2020 |
| Country | United States | United States |
| Employees | N/A | 80000 |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.0B | 2.8B |
| IPO Year | 2005 | 2021 |
| Metric | MDGL | KD |
|---|---|---|
| Price | $445.18 | $12.43 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 5 |
| Target Price | ★ $674.45 | $35.25 |
| AVG Volume (30 Days) | 268.7K | ★ 3.2M |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 41.32 | ★ 170.95 |
| EPS | N/A | ★ 0.77 |
| Revenue | $180,133,000.00 | ★ $15,057,000,000.00 |
| Revenue This Year | $58.28 | $3.96 |
| Revenue Next Year | $46.80 | $0.41 |
| P/E Ratio | ★ N/A | $15.93 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $265.00 | $10.10 |
| 52 Week High | $615.00 | $43.74 |
| Indicator | MDGL | KD |
|---|---|---|
| Relative Strength Index (RSI) | 47.26 | 38.19 |
| Support Level | $416.43 | $11.34 |
| Resistance Level | $446.51 | $13.81 |
| Average True Range (ATR) | 15.99 | 0.48 |
| MACD | 3.64 | 0.35 |
| Stochastic Oscillator | 53.39 | 21.91 |
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.
Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives. The company's reportable segments consist of the following: Principal Markets which represents its operations in operations in Australia / New Zealand, Canada, France, Germany, India, Italy, Spain, Portugal, and the United Kingdom / Ireland, United States, Japan, and Strategic Markets. It derives maximum revenue from the United States.